Download Now: 7 Unstoppable Growth Engines of India's $10 Trillion Bull Run...
Here is the latest financial fact sheet of MANKIND PHARMA. For more details, see the MANKIND PHARMA quarterly results and MANKIND PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -1.3 |
No. of shares | m | 400.59 |
1 Week | % | -1.2 |
1 Month | % | 5.3 |
1 Year | % | - |
52 week H/L | Rs | 2,488.7/1,240.8 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
MANKIND PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | NA | NA | |
Low | Rs | NA | NA | NA | NA | NA | |
Sales per share (Unadj.) | Rs | 124.3 | 146.6 | 155.1 | 194.3 | 218.4 | |
Earnings per share (Unadj.) | Rs | 15.2 | 26.4 | 32.3 | 36.3 | 32.7 | |
Diluted earnings per share | Rs | 15.2 | 26.4 | 32.3 | 36.3 | 32.7 | |
Cash flow per share (Unadj.) | Rs | 17.0 | 28.8 | 35.2 | 40.4 | 40.8 | |
Dividends per share (Unadj.) | Rs | 4.45 | 3.10 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 4.45 | 3.10 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 70.5 | 87.0 | 117.9 | 153.7 | 185.6 | |
Adj. book value per share | Rs | 70.5 | 87.0 | 117.9 | 153.7 | 185.6 | |
Shares outstanding (eoy) | m | 400.59 | 400.59 | 400.59 | 400.59 | 400.59 | |
Price / Sales ratio | x | 0 | 0 | 0 | 0 | 0 | |
Avg P/E ratio | x | 0 | 0 | 0 | 0 | 0 | |
P/CF ratio (eoy) | x | 0 | 0 | 0 | 0 | 0 | |
Price / Book Value ratio | x | 0 | 0 | 0 | 0 | 0 | |
Dividend payout | % | 29.2 | 11.8 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total wages/salary | Rs m | 10,948 | 13,355 | 14,158 | 16,206 | 19,185 |
MANKIND PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 49,800 | 58,719 | 62,144 | 77,816 | 87,494 | |
Other income | Rs m | 529 | 1,038 | 1,709 | 1,960 | 1,286 | |
Total revenues | Rs m | 50,329 | 59,757 | 63,854 | 79,776 | 88,780 | |
Gross profit | Rs m | 9,350 | 14,562 | 16,608 | 20,050 | 19,144 | |
Depreciation | Rs m | 690 | 991 | 1,190 | 1,666 | 3,259 | |
Interest | Rs m | 442 | 232 | 212 | 598 | 458 | |
Profit before tax | Rs m | 8,746 | 14,377 | 16,916 | 19,746 | 16,712 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,641 | 3,816 | 3,986 | 5,216 | 3,616 | |
Profit after tax | Rs m | 6,105 | 10,561 | 12,930 | 14,530 | 13,097 | |
Gross profit margin | % | 18.8 | 24.8 | 26.7 | 25.8 | 21.9 | |
Effective tax rate | % | 30.2 | 26.5 | 23.6 | 26.4 | 21.6 | |
Net profit margin | % | 12.3 | 18.0 | 20.8 | 18.7 | 15.0 |
MANKIND PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 19,431 | 28,195 | 38,796 | 44,038 | 43,246 | |
Current liabilities | Rs m | 10,241 | 12,507 | 13,534 | 26,235 | 18,631 | |
Net working cap to sales | % | 18.5 | 26.7 | 40.7 | 22.9 | 28.1 | |
Current ratio | x | 1.9 | 2.3 | 2.9 | 1.7 | 2.3 | |
Inventory Days | Days | 65 | 59 | 99 | 60 | 68 | |
Debtors Days | Days | 161 | 330 | 19 | 182 | 240 | |
Net fixed assets | Rs m | 20,854 | 22,031 | 24,170 | 47,016 | 53,578 | |
Share capital | Rs m | 401 | 401 | 401 | 401 | 401 | |
"Free" reserves | Rs m | 27,830 | 34,453 | 46,819 | 61,152 | 73,951 | |
Net worth | Rs m | 28,231 | 34,853 | 47,220 | 61,552 | 74,352 | |
Long term debt | Rs m | 251 | 582 | 577 | 492 | 231 | |
Total assets | Rs m | 40,835 | 50,253 | 63,236 | 91,085 | 96,857 | |
Interest coverage | x | 20.8 | 62.9 | 81.0 | 34.0 | 37.5 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.2 | 1.2 | 1.0 | 0.9 | 0.9 | |
Return on assets | % | 16.0 | 21.5 | 20.8 | 16.6 | 14.0 | |
Return on equity | % | 21.6 | 30.3 | 27.4 | 23.6 | 17.6 | |
Return on capital | % | 32.3 | 41.2 | 35.8 | 32.8 | 23.0 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 2.1 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 1,795 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 1,795 | |
Fx outflow | Rs m | 0 | 0 | 0 | 0 | 871 | |
Net fx | Rs m | 0 | 0 | 0 | 0 | 925 |
MANKIND PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 6,004 | 10,722 | 11,372 | 9,198 | 18,133 | |
From Investments | Rs m | -4,443 | -4,392 | -12,222 | -13,691 | -10,541 | |
From Financial Activity | Rs m | -1,751 | -5,270 | -78 | 6,046 | -7,397 | |
Net Cashflow | Rs m | -191 | 1,097 | -924 | 1,557 | 218 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Ramesh Juneja | COMP SEC: Pradeep Chugh | YEAR OF INC: 1991 | BSE CODE: 543904 | FV (Rs): 1 | DIV YIELD (%): - |
Read: MANKIND PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare MANKIND PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.